about
A multicenter, prospective, randomized, double-blind study to evaluate the safety and efficacy of Saroglitazar 2 and 4 mg compared with placebo in type 2 diabetes mellitus patients having hypertriglyceridemia not controlled with atorvastatin therapyA Multicenter, Prospective, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Saroglitazar 2 and 4 mg Compared to Pioglitazone 45 mg in Diabetic Dyslipidemia (PRESS V).A Prospective, Multicentre, Open-Label Single-Arm Exploratory Study to Evaluate Efficacy and Safety of Saroglitazar on Hypertriglyceridemia in HIV Associated Lipodystrophy.Pharmacokinetics, safety, and tolerability of saroglitazar (ZYH1), a predominantly PPARα agonist with moderate PPARγ agonist activity in healthy human subjects.A prospective, randomized, double-blind, multicentre, parallel-group, active controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia; ZRC-3197) and adalimumab (Humira) in patients with rheumatoid arthritis.Drug approvals in India
P50
description
researcher ORCID ID = 0000-0002-7077-8024
@en
wetenschapper
@nl
name
Rajendrakumar H Jani
@ast
Rajendrakumar H Jani
@en
Rajendrakumar H Jani
@nl
type
label
Rajendrakumar H Jani
@ast
Rajendrakumar H Jani
@en
Rajendrakumar H Jani
@nl
prefLabel
Rajendrakumar H Jani
@ast
Rajendrakumar H Jani
@en
Rajendrakumar H Jani
@nl
P106
P31
P496
0000-0002-7077-8024